Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 6 Quartile-based stratification of biomarkers and clinical prognostic factors

From: Prognostic and diagnostic value of PVR gene and protein levels, serum amylase, and urinary IGFBP-7 and TIMP-2 biomarkers in multiple myeloma

Biomarker Quartile

ISS stage III (%)

TP53 mutation (%)

Median OS (Months)

p-value

PVR (Q4 vs. Q1)

78% vs. 12%

42% vs. 8%

36 vs. 58

<0.001

IGFBP-7 (Q4 vs. Q1)

65% vs. 20%

35% vs. 10%

40 vs. 55

0.003

Amylase (Q4 vs. Q1)

70% vs. 15%

30% vs. 5%

38 vs. 60

0.001

  1. Q1 lowest quartile, Q4 highest quartile. P-values reflect differences between quartiles 1 and 4 using the chi-square test for categorical variables (ISS, TP53) and the log-rank test for survival (OS). This stratified analysis demonstrates the incremental prognostic value of biomarker expression across the clinical spectrum of MM
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us